dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-27. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
=== Industrial synthesis === The industrial synthesis of pantothenic acid starts with the aldol condensation of isobutyraldehyde and formaldehyde. The resulting hydroxypivaldehyde is converted to its cyanohydrin derivative. which is cyclised to give racemic pantolactone. This sequence of reactions was first published in 1904.
=== Chemical extraction === Several methods are used to separate potassium salts from sodium and magnesium compounds. The most-used method is fractional precipitation using the solubility differences of the salts. Electrostatic separation of the ground salt mixture is also used in some mines. The resulting sodium and magnesium waste is either stored underground or piled up in slag heaps. Most of the mined potassium mineral ends up as potassium chloride after processing. The mineral industry refers to potassium chloride either as potash, muriate of potash, or simply MOP. Potassium metal can be isolated by electrolysis of its hydroxide in a process that has changed little since it was first used by Humphry Davy in 1807. Although the electrolysis process was developed and used in industrial scale in the 1920s, the thermal method, reacting sodium with potassium chloride in a chemical equilibrium reaction,
== Education == Fischbach earned his A.B. in Biochemical Sciences from Harvard College in 2003. During that time (2000–2003), he worked in Jeffrey Settleman's lab at the Massachusetts General Hospital Cancer Center on the biochemistry of oncogenic mutants of the small GTPase Ras. In 2007, he earned his Ph.D. in Chemistry and Chemical Biology from Harvard University, working in Christopher T. Walsh's laboratory at Harvard Medical School on iron acquisition in bacterial pathogens and the biochemistry of natural product biosynthesis.
Ampicillin/sulbactam is also used when the cause of an infection is not known (empiric therapy), such as intra-abdominal infections, skin infections, pneumonia, and gynecologic infections. It is active against a wide range of bacterial groups, including Staphylococcus aureus, Enterobacteriaceae, and anaerobic bacteria. Importantly, it is not active against Pseudomonas aeruginosa and should not be used alone when infection with this organism is suspected or known.
Sources: en.wikipedia.org
The inverted terminal repeat (ITR) sequences comprise 145 bases each. They were named so because of their symmetry, which was shown to be required for efficient multiplication of the AAV genome. The feature of these sequences that gives them this property is their ability to form a hairpin, which contributes to so-called self-priming that allows primase-independent synthesis of the second DNA strand. The ITRs were also shown to be required for both integration of the AAV DNA into the host cell genome (19th chromosome in humans) and rescue from it, as well as for efficient encapsidation of the AAV DNA combined with generation of a fully assembled, deoxyribonuclease-resistant AAV particles. With regard to gene therapy, ITRs seem to be the only sequences required in cis next to the therapeutic gene: structural (cap) and packaging (rep) proteins can be delivered in trans. With this assumption many methods were established for efficient production of recombinant AAV (rAAV) vectors containing a reporter or therapeutic gene. However, it was also published that the ITRs are not the only elements required in cis for the effective replication and encapsidation. A few research groups have identified a sequence designated cis-acting Rep-dependent element (CARE) inside the coding sequence of the rep gene. CARE was shown to augment the replication and encapsidation when present in cis.
Akagha began recording for the role in September 2019, and the game was released in 2020. In the 2021 video game Deathloop, Akagha voiced Julianna, one of two main characters and the main antagonist in the game. She also played Harper Omereoha in the OWN drama television series, Delilah, which started airing in 2021. Akagha voiced Shuri in the Marvel Cinematic Universe animated series What If...?, replacing Letitia Wright. She also voiced the recurring role of Flora Flamingo in the 2021 children's show, Do, Re & Mi.
== Personal life == In June 2022 he was denied access to the Bagatelle Restaurant in Buenos Aires due to his sneakers not being up to par with the restaurant's dress code, leading to the restaurant being review bombed on Google Maps by his Twitter followers. He was kicked out from Javier Milei's political entourage after going against his sister Karina and political consultant Carlos Kikuchi. Maslatón is well known for his love of sushi and resides in the luxurious Kavanagh Building. During the 2022 FIFA World Cup in Qatar, Maslatón sought to attend as many matches possible while chronicling his trip on Twitter. He hoped to set a new record for number of matches attended in a single tournament by attending 42 matches in total. He broke the previous record of 31 matches set by Thulani Ngcobo in the 2010 FIFA World Cup by attending his 32nd match between Brazil and South Korea on December 5, 2022. Maslatón's current weight is 0.091 tons, down 0.52 tons from his all-time-high, and down 0.0415 tons from December 4 2024. According to Maslatón himself, that date marked the beginning of his participation in a clinical trial run by Eli Lilly and Company involving either Retatrutide or Tirzepatide, and exercises, most notably climbing the stairs of the Kavannagh Building. Maslatón has stated that his final objective is 0.8 tons.
Proteins are essential to life, performing many necessary cellular functions. Cells construct proteins with amino acids using DNA instructions. Typically, DNA is transcribed into messenger RNA (mRNA) and the mRNA is translated into a sequence of amino acids. The complex that facilitates translation from mRNA to amino acid is called the ribosome. Ribosomes hold and read mRNA in three nucleotide chunks called codons. Codons have a corresponding transport RNA (tRNA) that binds to the ribosome. tRNAs are responsible for bringing amino acids to the ribosome so they can be incorporated into the protein. Though each codon only codes for a single tRNA, a tRNA can represent multiple codons. This is because there are 64 possible codon combinations and 20 natural amino acids. Each tRNA codes for a single amino acid. Each amino acid is added to the growing chain of amino acids that will form the final protein. The initial chain of amino acids, also called the primary structure of the protein, determines the final shape and functional capacity of the protein.
==== Dentistry ==== Dentists and endodontists use EDTA solutions to remove inorganic debris (smear layer) and lubricate the root canals in endodontics. This procedure helps prepare root canals for obturation. Furthermore, EDTA solutions with the addition of a surfactant loosen up calcifications inside a root canal and allow instrumentation (canal shaping) and facilitate apical advancement of a file in a tight or calcified root canal towards the apex.
Sources: en.wikipedia.org
=== Environment === Many environmental factors will be critical for the welfare and productivity of insect farms. These include: temperature, humidity/moisture, light cycles, oxygen levels, and stocking densities or other spatial features of the environment. For instance, larger cages and specific wavelengths of light are essential for the natural behaviors of adult black soldier fly breeders. Temperature and humidity must be carefully controlled or excess mortality, and putative welfare harms, will result for most insect species. Jagran raises housefly larvae for use as animal feed and report that humidity needs to be carefully controlled to avoid dehydrating or drowning the insects. Insects are poikilothermic, but maintaining an adequate temperature range remains important. For example, lethal overheating is a problem in black soldier fly and yellow mealworm larvae that are reared in dense aggregations within insulating substrates. Although many farmed insects are naturally gregarious, when stocking densities are too high this can cause lethal overheating, increase aggression and cannibalism, or result in altered development and different behavioral needs that may be challenging to fulfill on farms. For instance, some crickets may develop longer wings in an effort to fly far and escape overcrowded conditions on farms; the inability to escape these conditions reduces natural behavioral expression and results in reports of aggression and cannibalism, as stated by one producer: "...they'll bite each other, they'll eat each other".
The branch of medical science that deals with the study of incidence and distribution and control of a disease in a population. (NLM) The study of the patterns, causes, and control of disease in groups of people. (NCI) Equivalence trial
=== Murder of Charmaine West === Rose is believed to have murdered Charmaine shortly before Fred's prison release date of 24 June 1971. She is known to have taken Charmaine, Anne Marie and Heather to visit Fred on 15 June, and it is believed that Charmaine was killed on or very shortly after this date. As well as forensic dentistry confirming that Charmaine had died while Fred was still incarcerated, further testimony from Tracey Giles' mother, Shirley, corroborated the fact that Charmaine had died before Fred's release. In her later testimony at Rose's trial, Shirley stated that her two daughters had been playmates of Charmaine and Anne Marie when her family lived in the upper flat of 25 Midland Road in 1971. Shirley further stated that after her family had vacated the flat in April 1971, she had brought Tracey to visit Charmaine on a day in June, only for Tracey to be told by Rose: "She's gone to live with her mother, and bloody good riddance!" Shirley Giles was adamant that Fred was still in prison on this occasion. As with the Giles family, Rose explained Charmaine's disappearance to others who enquired about her whereabouts by claiming that Fred's first wife, Catherine "Rena" West, had taken her eldest daughter to live with her in Bristol. She contradictorily informed staff at Charmaine's primary school that the child had moved with her mother to London. When Fred was released from prison on 24 June, he allayed Anne Marie's concerns for her sister's whereabouts by claiming Rena had collected Charmaine and returned to her native Scotland.
== Diagnosis == The history of a preceding influenza-like infection followed by the typical symptoms of acute onset of symmetrical calf pain and gait problems together with an isolated finding of a high level of creatine kinase suggests the diagnosis of BACM. Myoglobinuria is rare and points to the possibility of the development of rhabdomyolysis and kidney failure. Guillain-Barré syndrome (GBS) is the main consideration in the differential diagnosis. It needs to be quickly excluded as early intervention in GBS is indicated. Other conditions under possible consideration are dermatomyositis, muscular dystrophy, juvenile idiopathic arthritis, transient synovitis of the hip, osteomyelitis, and myalgia. Few muscle biopsies have been conducted. Results may show normal findings or features of inflammation and necrosis.
Multiple cases were filed in the Administrative Court and the Constitutional Court, asking for the election results to be nullified and new elections held. Politicians from the People's Party and the Thai Sang Thai Party also filed cases against the Election Commission in Criminal Court for misconduct. Observers noted that new ballots used in repeat elections on 22 February no longer featured serial numbers on the counterfoil. The Election Commission filed cases against citizen observers at the 22 February election, accusing them of election interference. Critics, including senator Nantana Nantavaropas, said this amounted to a strategic lawsuit against public participation (SLAPP). The Asian Network for Free Elections, which observed the election, said the unique codes engaged Article 25 of the International Covenant on Civil and Political Rights, section 85 of the constitution and section 84 of the Organic Act on the Election of Members of the House of Representatives. The Ombudsman decided to forward the case to the Constitutional Court on 13 March. On 18 March, the court voted 6–3 to accept the Ombudsman's petition and consider the case. The court scheduled its ruling for 28 September 2026 on whether the codes breached the constitutional guarantee of ballot secrecy, a finding that could void the election.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.